Sionna Therapeutics logo
Sionna Therapeutics
SION | NASDAQ
Chart Builder DCF Calculator
$3.12
-$0.21 (-6.31%)
At close: Nov 16, 2026, 4:00 PM ET
$3.11
-$0.01 (-0.33%)
After-hours: Nov 16, 2026, 6:53 PM ET

Sionna Therapeutics Company Profile

Company profile explained

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Key Executives

Name Position
Michael Cloonan President, Chief Executive Officer & Director
Jennifer Fitzpatrick Chief Legal Officer & Head of Program Management
Vanya Sagar Chief People Officer
Andy Chu Vice President of Information & Technology
Caroline Stark Beer Chief Business Officer
Cecile Le Camus VP & Head of Medical Affairs
Charlotte McKee Chief Medical Officer & Head of Research and Development
Elena H. Ridloff CFO & Chief Business Officer
Erica Iorio VP of Finance & Controller
Greg Hurlbut Co-Founder & Senior Vice President of Discovery Research
Juliet Labadorf Senior Director of Investor Relations & Corporate Development
Kenneth A. Lock Chief Commercial Officer
Mara Furlow Senior Vice President of Global Regulatory Affairs & Quality
Mark Munson Co-founder
Mark Trone Senior VP & Head of CMC
Meghan Bagshaw Vice President & Chief of Staff to CMO
Roxanne McGrath Vice President of Head of Human Resources
Sarah J. Spencer Vice President of Corporate Communications

Latest SEC Filings

Date Type Title
Sep 21, 2026 SC 13D/A [Amend] Filing
Sep 21, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 14, 2026 8-K Current Report
Aug 10, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
View All SEC Filings ➞
Sionna Therapeutics
Sionna Therapeutics logo
Country United States
IPO Date Feb 7, 2025
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Michael Cloonan

Contact Details

21 Hickory Drive Suite 500 Waltham, Massachusetts 02451 United States

Stock Details

Ticker Symbol SION
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002036042
CUSIP Number 829401108
ISIN Number US8294011080
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.